Cargando…
Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania
BACKGROUND: In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781949/ https://www.ncbi.nlm.nih.gov/pubmed/17224049 http://dx.doi.org/10.1186/1475-2875-6-2 |
_version_ | 1782132002635382784 |
---|---|
author | Schönfeld, Mirjam Barreto Miranda, Isabel Schunk, Mirjam Maduhu, Ibrahim Maboko, Leonard Hoelscher, Michael Berens-Riha, Nicole Kitua, Andrew Löscher, Thomas |
author_facet | Schönfeld, Mirjam Barreto Miranda, Isabel Schunk, Mirjam Maduhu, Ibrahim Maboko, Leonard Hoelscher, Michael Berens-Riha, Nicole Kitua, Andrew Löscher, Thomas |
author_sort | Schönfeld, Mirjam |
collection | PubMed |
description | BACKGROUND: In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (pfdhfr) and dihydropteroate synthase (pfdhps) genes. METHODS: In samples from 86 patients with uncomplicated Plasmodium falciparum malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the pfcrt and pfmdr1 genes which are associated with CQ resistance and in pfdhfr and pfdhps, conferring SP resistance, as well in cytb which is linked to resistance to atovaquone. RESULTS: Pfcrt T76 occurs in 50% and pfmdr1 Y86 in 51.7%. Pfdhfr triple mutations coexisting with pfdhps double mutations were detected in 64.3% of the P. falciparum isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the cytb gene were not detected. CONCLUSION: These findings of a high prevalence of mutations conferring SP resistance correspond to data of in vivo SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy. |
format | Text |
id | pubmed-1781949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-17819492007-01-26 Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania Schönfeld, Mirjam Barreto Miranda, Isabel Schunk, Mirjam Maduhu, Ibrahim Maboko, Leonard Hoelscher, Michael Berens-Riha, Nicole Kitua, Andrew Löscher, Thomas Malar J Research BACKGROUND: In Tanzania, drug-resistant malaria parasites are an increasing public health concern. Because of widespread chloroquine (CQ) resistance Tanzania changed its first line treatment recommendations for uncomplicated malaria from CQ to sulfadoxine-pyrimethamine (SP) in 2001. Loss of SP sensitivity is progressing rapidly. SP resistance is associated with mutations in the dihydrofolate reductase (pfdhfr) and dihydropteroate synthase (pfdhps) genes. METHODS: In samples from 86 patients with uncomplicated Plasmodium falciparum malaria from Mbeya and Matema, Mbeya region, south-western Tanzania, the occurrence of mutations was investigated in the pfcrt and pfmdr1 genes which are associated with CQ resistance and in pfdhfr and pfdhps, conferring SP resistance, as well in cytb which is linked to resistance to atovaquone. RESULTS: Pfcrt T76 occurs in 50% and pfmdr1 Y86 in 51.7%. Pfdhfr triple mutations coexisting with pfdhps double mutations were detected in 64.3% of the P. falciparum isolates. This quintuple mutation is seen as a possible predictive molecular marker for SP treatment failure. Mutations of the cytb gene were not detected. CONCLUSION: These findings of a high prevalence of mutations conferring SP resistance correspond to data of in vivo SP efficacy studies in other regions of Tanzania and underline the recommendation of changing first-line treatment to artemisinin-based combination therapy. BioMed Central 2007-01-15 /pmc/articles/PMC1781949/ /pubmed/17224049 http://dx.doi.org/10.1186/1475-2875-6-2 Text en Copyright © 2007 Schönfeld et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Schönfeld, Mirjam Barreto Miranda, Isabel Schunk, Mirjam Maduhu, Ibrahim Maboko, Leonard Hoelscher, Michael Berens-Riha, Nicole Kitua, Andrew Löscher, Thomas Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania |
title | Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania |
title_full | Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania |
title_fullStr | Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania |
title_full_unstemmed | Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania |
title_short | Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania |
title_sort | molecular surveillance of drug-resistance associated mutations of plasmodium falciparum in south-west tanzania |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781949/ https://www.ncbi.nlm.nih.gov/pubmed/17224049 http://dx.doi.org/10.1186/1475-2875-6-2 |
work_keys_str_mv | AT schonfeldmirjam molecularsurveillanceofdrugresistanceassociatedmutationsofplasmodiumfalciparuminsouthwesttanzania AT barretomirandaisabel molecularsurveillanceofdrugresistanceassociatedmutationsofplasmodiumfalciparuminsouthwesttanzania AT schunkmirjam molecularsurveillanceofdrugresistanceassociatedmutationsofplasmodiumfalciparuminsouthwesttanzania AT maduhuibrahim molecularsurveillanceofdrugresistanceassociatedmutationsofplasmodiumfalciparuminsouthwesttanzania AT mabokoleonard molecularsurveillanceofdrugresistanceassociatedmutationsofplasmodiumfalciparuminsouthwesttanzania AT hoelschermichael molecularsurveillanceofdrugresistanceassociatedmutationsofplasmodiumfalciparuminsouthwesttanzania AT berensrihanicole molecularsurveillanceofdrugresistanceassociatedmutationsofplasmodiumfalciparuminsouthwesttanzania AT kituaandrew molecularsurveillanceofdrugresistanceassociatedmutationsofplasmodiumfalciparuminsouthwesttanzania AT loscherthomas molecularsurveillanceofdrugresistanceassociatedmutationsofplasmodiumfalciparuminsouthwesttanzania |